Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?

Cho, Yeoungjee and Johnson, David W. (2014) Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?. Current Opinion in Nephrology and Hypertension, 23 2: 192-197. doi:10.1097/01.mnh.0000441046.13912.1f


Author Cho, Yeoungjee
Johnson, David W.
Title Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?
Journal name Current Opinion in Nephrology and Hypertension   Check publisher's open access policy
ISSN 1062-4821
1473-6543
Publication date 2014-03
Year available 2014
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1097/01.mnh.0000441046.13912.1f
Open Access Status
Volume 23
Issue 2
Start page 192
End page 197
Total pages 6
Place of publication London, United Kingdom
Publisher Lippincott Williams & Wilkins
Collection year 2015
Language eng
Subject 2727 Nephrology
2724 Internal Medicine
Formatted abstract
Purpose of review: This review will examine the impact of neutral pH, low glucose degradation product (GDP) peritoneal dialysis fluid use on patient-level clinical outcomes in peritoneal dialysis patients.

Recent findings: Recently published results from the balANZ trial and a meta-analysis suggest that the use of neutral pH, low GDP peritoneal dialysis fluids leads to better preservation of residual renal function, including residual diuresis, without added harmful effects. The impact of neutral pH, low GDP peritoneal dialysis fluids on other clinical outcomes (e.g. peritonitis) remains uncertain due to conflicting results from randomized controlled trials. A meta-analysis was unable to clarify this further due to generally suboptimal trial quality and insufficient statistical power.

Summary: At present, based on the best available evidence, the use of neutral pH, low GDP peritoneal dialysis fluids is associated with some important clinical benefits without added harm. Further studies in the area are needed to establish the cost-effectiveness of this therapy and to clarify the effects of biocompatible fluids on patient-level outcomes, such as peritonitis, quality of life, technique survival and patient survival.
Keyword Biocompatible
Glucose degradation product
Peritoneal dialysis fluid
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 04 Mar 2014, 00:25:06 EST by System User on behalf of School of Medicine